> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Reg Review Period on Pharming’s Ruconest
- URL: https://www.fdaweb.com/reg-review-period-on-pharmings-ruconest/
- Published: 2016-11-22T12:00:00.000Z
- Updated: 2026-09-14T21:49:59.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5137410

*Federal Register* Notice: FDA has determined the regulatory review period for Pharming Group’s Ruconest for patent extension purposes — 3,502 days. Of this time, 3,045 days occurred during the testing phase of the regulatory review period, while 457 days occurred during the approval phase. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2016-11-22/pdf/2016-28046.pdf?ref=fdaweb.com).